US4960797A
Expired / Lapsed
US
⏱️ 0.0 years remaining
N-2[(4-fluoro-phenyl)-1-methyl]-2-ethyl-N-methyl-N-propynyl amine and the method of use thereof
Assignee: Chinoin Private Co Ltd
•
Filing: 1989-02-15
•
Granted: 1990-10-02
•
Expires: 2009-02-15
Abstract
Abstract The invention relates to the new N-[2-/4-fluorophenyl/-1-methyl]-ethyl-N-methyl-N-propynyl amine of the Formula I <IMAGE> (I) and isomers and salts thereof. The compound of the formula I is useful as a selective MAO inhibitor.
Inventors
- 👤 Zoltan Ecsery, deceased
- 👤 Jozsef Knoll
- 👤 Eva Somfai
- 👤 Zoltan Torok
- 👤 Eva Szinnyei
- 👤 Karoly Mozsolics
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 19:47
CPC Classifications
C; C07; C07C; C07C211/00; C07C211/01; C07C211/26; C07C211/29; A; A61; A61P; A61P13/00; A61P13/02; A61P15/00; A61P25/00; A61P25/02; A61P25/24; A61P25/26; A61P25/28; A61P43/00
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
15 words
A compound of the Formula (I) ##STR17## or a pharmaceutically acceptable acid addition salt thereof.
Claim 2
Dependent Claim
15 words
A compound of the Formula (I) ##STR17## or a pharmaceutically acceptable acid addition salt thereof.
Claim 3
Dependent Claim
15 words
(±)-N-2[(4-fluoro-phenyl)-1-methyl]-2-ethyl-N-methyl-N-propynyl amine or a pharmaceutically acceptable acid addition salt thereof as defined in claim 1.
Claim 4
Dependent Claim
15 words
(-)-N-2[(4-fluoro-phenyl)-1-methyl]-2-ethyl-N-methyl-N-propynyl amine or a pharmaceutically acceptable acid addition salt thereof as defined in claim 1.
Claim 5
Dependent Claim
72 words
A pharmaceutical composition to counteract the consequences of decrease in brain dopamine concentration to facilitate dopaminergic modulation in the brain without acting on the postsynaptic dopamine receptor, and which possesses a selective B-type MAO-inhibiting activity along with a dopamine-and tyramine-uptake inhibiting activity, which comprises a therapeutically effective amount of the compound of the Formula (I) ##STR18## or a pharmaceutically acceptable acid addition salt thereof, in combination with a pharmaceutically acceptable inert carrier.
Claim 6
Dependent Claim
72 words
A pharmaceutical composition to counteract the consequences of decrease in brain dopamine concentration to facilitate dopaminergic modulation in the brain without acting on the postsynaptic dopamine receptor, and which possesses a selective B-type MAO-inhibiting activity along with a dopamine-and tyramine-uptake inhibiting activity, which comprises a therapeutically effective amount of the compound of the Formula (I) ##STR18## or a pharmaceutically acceptable acid addition salt thereof, in combination with a pharmaceutically acceptable inert carrier.
Claim 7
Independent Claim
81 words
A method of treating a mammalian subject to counteract the consequences of decrease in brain dopamine concentration, to facilitate dopaminergic modulation in the brain without acting on the postsynaptic dopamine receptor by inhibiting selectively the B-type monoamine oxidase enzyme while also inhibiting tyramine and dopamine uptake, which comprises the step of administering to a mammalian subject in need of said treatment a therapeutically effective amount of the compound of the Formula (I) ##STR19## or a pharmaceutically acceptable acid addition salt thereof.
Claim 8
Independent Claim
81 words
A method of treating a mammalian subject to counteract the consequences of decrease in brain dopamine concentration, to facilitate dopaminergic modulation in the brain without acting on the postsynaptic dopamine receptor by inhibiting selectively the B-type monoamine oxidase enzyme while also inhibiting tyramine and dopamine uptake, which comprises the step of administering to a mammalian subject in need of said treatment a therapeutically effective amount of the compound of the Formula (I) ##STR19## or a pharmaceutically acceptable acid addition salt thereof.
Claim 9
Dependent Claim
40 words
The method of treatment defined in claim 5 wherein the compound of the Formula (I) or the pharmaceutically acceptable acid addition salt thereof is administered to the mammalian subject in a dose of 0.05 to 0.25 mg/kg of body weight.
References Cited (Backward Citations)
US3429922A
Cited
US3485874A
Cited
US3496195A
Cited
US4314081A
Cited
US4105695A
Cited
US4156017A
Cited
US4835315A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-10-01 | 1994-04-02 | 1994-10-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-10-01 | 1998-04-02 | 1998-10-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-10-01 | 2002-04-02 | 2002-10-02 | $7700.00 | Window Closed / Lapsed |